METXF (ME Therapeutics Holding) Operating Margin %: 0.00% (As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

METXF ME Therapeutics Holding Inc METXF
14 GF Score
Price $3.25
! 1 Warning Sign
View Full Analysis

What is ME Therapeutics Holding Operating Margin %?

ME Therapeutics Holding METXF 14 Operating Margin % is 0.00% as of May. 2026. GuruFocus rates METXF with a GF Score™ of 14/100. The stock has 1 warning sign investors should review. Among 940 Biotechnology companies, ME Therapeutics Holding ranks worse than 106382.87% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. ME Therapeutics Holding's Operating Income for the three months ended in May. 2026 was $-0.29 Mil. ME Therapeutics Holding's Revenue for the three months ended in May. 2026 was $0.00 Mil. Therefore, ME Therapeutics Holding's Operating Margin % for the quarter that ended in May. 2026 was 0.00%.

The historical rank and industry rank for ME Therapeutics Holding's Operating Margin % or its related term are showing as below:


METXF's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -81.01
* Ranked among companies with meaningful Operating Margin % only.

ME Therapeutics Holding's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

ME Therapeutics Holding's Operating Income for the three months ended in May. 2026 was $-0.29 Mil. Its Operating Income for the trailing twelve months (TTM) ended in May. 2026 was $-1.01 Mil.


ME Therapeutics Holding  (OTCPK:METXF) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


ME Therapeutics Holding Operating Margin % Related Terms


ME Therapeutics Holding Operating Margin % Historical Data

* Premium members only.

The historical data trend for ME Therapeutics Holding's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ME Therapeutics Holding Operating Margin % Chart

ME Therapeutics Holding Annual Data
Trend Aug22 Aug23 Aug24 Aug25
Operating Margin %
0.00 0.00 0.00 0.00

ME Therapeutics Holding Quarterly Data
Aug22 Dec22 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

METXF vs VRTX, REGN, RVMD: Operating Margin % Comparison

For the Biotechnology subindustry, ME Therapeutics Holding's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ME Therapeutics Holding Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ME Therapeutics Holding's Operating Margin % distribution charts can be found below:

* The bar in red indicates where ME Therapeutics Holding's Operating Margin % falls into.


METXF
14GF Score
ME Therapeutics Holding Inc METXF
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ME Therapeutics Holding Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

ME Therapeutics Holding's Operating Margin % for the fiscal year that ended in Aug. 2025 is calculated as

Operating Margin %=Operating Income (A: Aug. 2025 ) / Revenue (A: Aug. 2025 )
=-0.883 / 0
= %

ME Therapeutics Holding's Operating Margin % for the quarter that ended in May. 2026 is calculated as

Operating Margin %=Operating Income (Q: May. 2026 ) / Revenue (Q: May. 2026 )
=-0.292 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of 0.00% mean?
ME Therapeutics Holding (METXF) has a Operating Margin % of 0.00% as of May. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on ME Therapeutics Holding and its competitors. According to the industry distribution chart, ME Therapeutics Holding ranks #999999 out of 940 companies in the Biotechnology industry.
Is ME Therapeutics Holding's Operating Margin % too high?
ME Therapeutics Holding's current Operating Margin % is 0.00%. Based on the distribution chart, ME Therapeutics Holding ranks #999999 out of 940 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, ME Therapeutics Holding has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does ME Therapeutics Holding's Operating Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, ME Therapeutics Holding ranks #999999 out of 940 companies for Operating Margin %. This places ME Therapeutics Holding in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on ME Therapeutics Holding and its competitors. ME Therapeutics Holding's current Operating Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ME Therapeutics Holding stock overvalued right now?
ME Therapeutics Holding (METXF) has a current Operating Margin % of 0.00%. The current Operating Margin % is 0.00%. ME Therapeutics Holding's overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For ME Therapeutics Holding (METXF), the current Operating Margin % is 0.00% as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ME Therapeutics Holding Business Description

Other Exchanges METX:Canada
Address 2665 East Mall, Room 249, Vancouver, BC, CAN, V6T 1Z4
ME Therapeutics Holding Inc is a preclinical stage biotechnology company working on cancer-fighting drugs in the field of Immuno Oncology, developing next-generation therapeutics targeting immune suppression in cancer. It is developing novel drugs that target myeloid cells to directly treat cancer and enhance the benefits of current Immuno Oncology drugs, such as checkpoint inhibitors in currently untreatable cancers. Immuno Oncology is a new area of cancer research that has been successful in treating previously untreatable cancers by targeting the immune system rather than the cancer directly, allowing a single drug to be used for multiple cancer types with mostly manageable side effects.
14GF Score

Get the complete analysis for METXF

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.25
Price